Advanced Melanoma Clinical Pipeline | 55+ Companies Driving the Future of Treatment

The Advanced Melanoma market is rapidly evolving with cutting-edge research and breakthrough therapies, driven by leading companies like OncoSec Medical, Immunocore, Sanofi, and TILT Biotherapeutics. These innovators are revolutionizing treatment approaches and shaping the future of Advanced Melanoma care, offering new hope for patients worldwide.

DelveInsight's 'Advanced Melanoma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Advanced Melanoma therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Advanced Melanoma pipeline domain.

For emerging Advanced Melanoma drugs, the Advanced Melanoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Advanced Melanoma Pipeline Report
• DelveInsight's Advanced Melanoma Pipeline analysis depicts a robust space with 55+ active players working to develop 60+ pipeline drugs for Advanced Melanoma treatment.
• The leading Advanced Melanoma companies include OncoSec Medical, Immunocore, Sanofi, TILT Biotherapeutics, Novartis Pharmaceuticals, Sumitomo Pharma, BioMed Valley Discoveries, Replimune, ImaginAb, Shanghai Pharmaceuticals, Seagen, Karyopharm Therapeutics, Hoffmann-La Roche, and others are evaluating their lead assets to improve the Advanced Melanoma treatment landscape.
• Key Advanced Melanoma pipeline therapies in various stages of development include BS001, IO102-IO103, SGN-BB228, Fianlimab + Cemiplimab, Tebentafusp, TAVO, and others.
• In January 2025, the FDA accepted the biologics license application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab (Opdivo) as a treatment for patients with advanced melanoma.
• In March 2025, the FDA approved cosibelimab-ipdl (UNLOXCYT) for adults with metastatic cutaneous squamous cell carcinoma (mcSCC) or locally advanced (lacSCC) who are ineligible for curative surgery or radiation. A news release from the drug's manufacturer, Checkpoint Therapeutics, states that the drug is the first and only programmed death ligand-1 (PD-L1)-blocking antibody to receive FDA approval for this indication.

Request a sample and discover the recent breakthroughs happening in the Advanced Melanoma pipeline landscape @ https://www.delveinsight.com/report-store/advanced-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Advanced Melanoma Overview
Advanced melanoma is a highly aggressive skin cancer known for its ability to metastasize and resist traditional treatments. Recent advancements in immunotherapy, targeted therapy, vaccines, and combination treatments have significantly improved management strategies, focusing on tumor reduction, preventing further spread, and symptom relief. The disease is influenced by environmental, genetic, and immunological factors, with key genetic mutations linked to melanoma including CDKN2A, CDK4, MC1R, and xeroderma pigmentosum, which impairs DNA repair. Notably, the incidence of melanoma is rising, particularly among White race females.

Early-stage melanoma is typically treated with surgical excision or Mohs micrographic surgery, offering a high chance of cure. However, metastatic melanoma presents greater challenges due to high genomic variability and resistance to treatment. Targeted therapies, such as Vemurafenib (ZELBORAF), a selective BRAFV600E inhibitor, have shown success but often lead to relapse within months due to pathway reactivation. Combining BRAF inhibitors with MEK or ERK inhibitors enhances effectiveness but increases toxicity. While a KRASG12C inhibitor has demonstrated tumor regression in KRAS-mutant models, its impact on NRAS-mutant melanomas remains uncertain. Major risk factors for melanoma include UV exposure, fair skin, numerous moles, genetic predisposition, immunosuppression, and older age, underscoring the importance of sun protection, regular skin checks, and genetic screening for high-risk individuals.

Find out more about Advanced Melanoma medication @ https://www.delveinsight.com/report-store/advanced-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Advanced Melanoma Treatment Analysis: Drug Profile
Tebentafusp: Immunocore
Tebentafusp is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma, and is the first molecule developed using Immunocore's ImmTAC technology platform designed to redirect and activate T cells to recognize and kill tumor cells. Tebentafusp has been granted Priority Review; Real Time Oncology Review; Breakthrough Therapy designation; Fast Track designation; and orphan drug designation by the FDA in the United States; orphan drug status in the European Union; and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of Advanced Melanoma.

TAVO: OncoSec Medical
TAVO is DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. TAVO is administered directly into the tumor using OncoSec's proprietary EP gene delivery system, which employs a series of momentary energy pulses. Those pulses are designed to increase the permeability of the cell membrane and facilitate uptake of IL-12 coded DNA into the tumor cells. The drug is currently being evaluated under Phase II clinical trials for the treatment of Advanced Melanoma.

Key Advanced Melanoma Therapies and Companies
• BS001: Binhui Biopharmaceutical
• IO102-IO103 : IO Biotech
• SGN-BB228: Pfizer
• Fianlimab + Cemiplimab: Regeneron Pharmaceuticals
• Tebentafusp: Immunocore
• TAVO: OncoSec Medical

Learn more about the novel and emerging Advanced Melanoma pipeline therapies @ https://www.delveinsight.com/report-store/advanced-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Advanced Melanoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide

Scope of the Advanced Melanoma Pipeline Report
• Coverage: Global
• Key Advanced Melanoma Companies: OncoSec Medical, Immunocore, Sanofi, TILT Biotherapeutics, Novartis Pharmaceuticals, Sumitomo Pharma, BioMed Valley Discoveries, Replimune, ImaginAb, Shanghai Pharmaceuticals, Seagen, Karyopharm Therapeutics, Hoffmann-La Roche, and others.
• Key Advanced Melanoma Pipeline Therapies: BS001, IO102-IO103, SGN-BB228, Fianlimab + Cemiplimab, Tebentafusp, TAVO, and others.

Dive deep into rich insights for drugs used for Advanced Melanoma treatment; visit @ https://www.delveinsight.com/report-store/advanced-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Advanced Melanoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Advanced Melanoma Pipeline Therapeutics
6. Advanced Melanoma Pipeline: Late-Stage Products (Phase III)
7. Advanced Melanoma Pipeline: Late-Stage Products (Phase III)
8. Advanced Melanoma Pipeline: Mid-Stage Products (Phase II)
9. Advanced Melanoma Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.